Neurotrophic Keratitis Market Analysis

Treatment Type (Surgical Intervention, Drugs)

The drugs segment in the neurotrophic keratitis market is the largest and is expected to reach 73% share by 2037. The market for neurotrophic keratitis is defined by a variety of medications created to handle the particular difficulties this illness presents. In all stages of NK, artificial tears are the primary line of treatment. Similar tasks are carried out by a variety of formulations based on polymers without preservatives. Elevated lubrication facilitates epithelialization by decreasing proinflammatory cytokine levels on the eye surface and the shear pressures produced by blinking. To treat the underlying cause of neurotrophic keratitis, nerve growth factor stimulators work to encourage the growth and healing of corneal nerves.

Application (Stage I, Stage II, Stage III)

Neurotrophic keratitis market share from the stage II segment is expected to cross 34% by 2037. The goal of stage II therapy is to encourage PED repair and stop a corneal ulcer from forming. Treatment options include amniotic membrane grafting, topical autologous serum application, lubricating ointments, therapeutic soft contact lenses or patching, tarsorrhaphy or botulinum-induced ptosis, and topical recombinant human nerve growth factor therapy. To fight bacterial infections, doctors can give antibiotic eye drops. Although topical corticosteroids may cause stromal melting, they can be used with caution to reduce inflammation.

Our in-depth analysis of the global market includes the following segments: